Phase 1 study of BLU-285 in patients with advanced systemic mastocytosis

Trial Profile

Phase 1 study of BLU-285 in patients with advanced systemic mastocytosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 10 Dec 2017 According to the American Society of Hematology media release, data from this study were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 01 Nov 2017 According to a Blueprint Medicines media release, data will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 02 Aug 2017 Blueprint Medicines completed enrollment in the dose escalation portion and began enrolling patients in the dose expansion portion of this clinical trial at the recommended dose of 300 mg once daily, as reported in a media release. The company anticipates providing updated data from this clinical trial by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top